🇺🇸 FDA

Company profile · Sponsor

Second

Second Affiliated Hospital of Soochow University

C146D1A · NMPA pharma CN
Pipeline
4
Drugs
0
Patents
0

Quick answer

Second (C146D1A) is a pharma company. headquartered in CN. listed on NMPA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker C146D1A
Exchange NMPA
Company type pharma
Headquarters CN

Pipeline (4)

Search pipeline →

  1. Cadonilimab

    Second

    Immunotherapy

    phase 2 small molecule active

    1 trial

  2. ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab

    Second

    Liver Cancer

    phase 2 small molecule active

    1 trial

  3. Vedolizumab

    Second

    Ulcerative Colitis (UC)

    approved mab completed

    1 trial

  4. Esketamine, Sulfentanil or/and Remifentanil

    Second

    Opioid Analgesic Adverse Reaction

    small molecule active

    1 trial

Frequently asked questions

What is Second?

Second (C146D1A) is a pharma company. headquartered in CN. listed on NMPA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Second sponsor?

We track 4 ClinicalTrials.gov-linked programs for Second, including Cadonilimab and 3 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Second company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.